| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
24051 |
| Drug |
Mirvetuximab |
| Brand |
Elahere® |
| Indication |
Mirvetuximab soravtansine (Elahere®) is indicated as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. |
| Rapid review commissioned |
17/12/2024 |
| Rapid review completed |
04/02/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Mirvetuximab soravtansine compared with the current standard of care. |
| Full HTA commissioned by the HSE |
26/02/2025 |
| Pre-submission consultation with Applicant |
03/04/2025 |
| Full submission received from Applicant |
28/11/2025 |
